abemaciclib

Showing 2 posts of 2 posts found.

Lilly’s breast cancer drug meets primary endpoint

March 21, 2017
Manufacturing and Production, Research and Development CDK 4/6 inhibitors, Eli Lilly, abemaciclib

Eli Lilly has announced that its trial of abemaciclib, in combination with fulvestrant, had met its primary endpoint of progression-free …

Interim analysis fails to show benefits for Lilly’s abemaciclib in advanced breast cancer

August 10, 2016
Research and Development Eli Lilly, abemaciclib, breast cancer

Eli Lilly has announced that, after a pre-planned interim analysis for their Phase III MONARCH2 trial, investigators have decided to …

The Gateway to Local Adoption Series

Latest content